Improvement of Recalcitrant Folliculitis Decalvans With Tirzepatide: A Case Report

Folliculitis decalvans (FD) is a chronic inflammatory alopecia characterized by painful, scarring lesions and recurrent flares, often complicated by secondary bacterial infections. Despite the use of topical and systemic anti-inflammatory or antimicrobial therapies, FD remains challenging to manage, with limited therapeutic advancements. We report a case of recalcitrant FD in a man in his 40s who experienced significant symptom improvement and hair regrowth following the initiation of tirzepatide for weight management. This case highlights a previously unreported therapeutic benefit of tirzepatide in FD, potentially mediated through its anti-inflammatory and immunomodulatory effects. As glucagon-like peptide 1 (GLP-1) receptor agonists gain recognition for their efficacy in other inflammatory skin conditions, such as psoriasis and hidradenitis suppurativa, this case supports further exploration of their role in managing FD and other refractory dermatologic diseases.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2024-12-23
DOI
https://doi.org/10.7759/cureus.76267
Citations
3
Primary Topic
Autoimmune Bullous Skin Diseases
Type
article
Field-Weighted Citation Impact
1.27
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Improvement of Recalcitrant Folliculitis Decalvans With Tirzepatide: A Case Report

John Murray, Michelle Pavlis, Kali Morrissette, Stefan Hansen
3 citations
Cureus
Autoimmune Bullous Skin Diseases
1.27
article

Improvement of Recalcitrant Folliculitis Decalvans With Tirzepatide: A Case Report

John Murray, Michelle Pavlis, Kali Morrissette, Stefan Hansen
article en
3 citations

Abstract

Folliculitis decalvans (FD) is a chronic inflammatory alopecia characterized by painful, scarring lesions and recurrent flares, often complicated by secondary bacterial infections. Despite the use of topical and systemic anti-inflammatory or antimicrobial therapies, FD remains challenging to manage, with limited therapeutic advancements. We report a case of recalcitrant FD in a man in his 40s who experienced significant symptom improvement and hair regrowth following the initiation of tirzepatide for weight management. This case highlights a previously unreported therapeutic benefit of tirzepatide in FD, potentially mediated through its anti-inflammatory and immunomodulatory effects. As glucagon-like peptide 1 (GLP-1) receptor agonists gain recognition for their efficacy in other inflammatory skin conditions, such as psoriasis and hidradenitis suppurativa, this case supports further exploration of their role in managing FD and other refractory dermatologic diseases.

CureusVol. 16(12)
Duke University (US), Durham VA Health Care System (US), Duke Medical Center (US), Duke University Hospital (US)
Zero hunger
Openalex Percentile: Top 19%
Autoimmune Bullous Skin Diseases
1.27
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Improvement of Recalcitrant Folliculitis Decalvans With Tirzepatide: A Case Report — John Murray, Michelle Pavlis, et al. · Cureus (2024) | TGRS Research Map | TGRS